Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
News Nov 30, 2010
Dr. William Lee, Senior Vice President, Research at Gilead Sciences, commented: “We are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead. Scientists from both companies have interacted well together and have made successful progress against some difficult targets. We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future”.
Commenting on the announcement, Selcia’s Managing Director, Dr. Hans Fliri said: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication. This represents a significant step forward in the development of Selcia’s Discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery. We look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives”.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019